Ideal or actual body weight to calculate CD34+cell doses for allogeneic hematopoietic stem cell transplantation?

被引:11
|
作者
Cilley, J
Rihn, C
Monreal, J
Gordon, LI
Singhal, S
Tallman, M
Williams, S
Winter, J
Mehta, J
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Hematopoiet Stem Cell Transplant Program, Chicago, IL 60611 USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
关键词
allogeneic hematopoietic stem cell transplantation; CD34+cells; engraftment; myeloid recovery; weight;
D O I
10.1038/sj.bmt.1704388
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The number of CD34+ cells infused influences hematologic recovery after transplantation. Limited data suggest that cell dose should be based on ideal (IBW) rather than actual (ABW) body weight for autotransplantation, but none in allografts. We compared the correlation between recovery to 0.5 x 10(9)/l neutrophils and the CD34+ cell dose based upon ABW and IBW in 78 allograft recipients. ABW was greater than or equal to25% over IBW in 47% of patients. The median CD34+ cell dose was 5.1 x 10(6)/kg IBW and 4.4 x 10(6)/kg ABW. The time to neutrophil recovery was 8-26 days ( median 12). There was a stronger inverse correlation between CD34+ cell dose/IBW and neutrophil recovery (r(2) = 0.160; P<0.0001) than between CD34+ cell dose/ABW and neutrophil recovery (r(2) = 0.138; P = 0.001). When neutrophil recovery in patients receiving <3 or <5 x 10(6) CD34+ cells/kg was compared to those receiving greater than or equal to3 or greater than or equal to5 x 10(6) CD34+ cells/kg, respectively, separately by IBW and ABW, the magnitude and significance of the differences were greater for IBW-based comparisons. These data suggest the CD34_ cell dose based on IBW is a better predictor of neutrophil recovery after allografting. Further work in a larger, more homogeneous group of patients is required to confirm this observation.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [1] Ideal or actual body weight to calculate CD34+cell doses for autologous hematopoietic stem cell transplantation?
    Ali, MY
    Oyama, Y
    Monreal, J
    Winter, JN
    Tallman, MS
    Williams, SF
    Singhal, S
    Gordon, LI
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2003, 31 (10) : 861 - 864
  • [2] Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?
    J Cilley
    C Rihn
    J Monreal
    L I Gordon
    S Singhal
    M Tallman
    S Williams
    J Winter
    J Mehta
    Bone Marrow Transplantation, 2004, 33 : 161 - 164
  • [3] Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?
    M Y Ali
    Y Oyama
    J Monreal
    J N Winter
    M S Tallman
    S F Williams
    S Singhal
    L I Gordon
    J Mehta
    Bone Marrow Transplantation, 2003, 31 : 861 - 864
  • [4] Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
    V Singh
    J Krishnamurthy
    S Duffey
    R Meagher
    M Villa
    J Monreal
    A Evens
    O Frankfurt
    J Altman
    L Gordon
    M Tallman
    S Williams
    J Winter
    S Singhal
    J Mehta
    Bone Marrow Transplantation, 2009, 43 : 301 - 305
  • [5] Optimizing the CD34+cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation
    Mehta, Jayesh
    Frankfurt, Olga
    Altman, Jessica
    Evens, Andrew
    Tallman, Martin
    Gordon, Leo
    Williams, Stephanie
    Winter, Jane
    Krishnamurthy, Jairam
    Duffey, Sara
    Singh, Veerpal
    Meagher, Richard
    Grinblatt, David
    Kaminer, Lynne
    Singhal, Seema
    LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1434 - 1441
  • [6] Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
    Singh, V.
    Krishnamurthy, J.
    Duffey, S.
    Meagher, R.
    Villa, M.
    Monreal, J.
    Evens, A.
    Frankfurt, O.
    Altman, J.
    Gordon, L.
    Tallman, M.
    Williams, S.
    Winter, J.
    Singhal, S.
    Mehta, J.
    BONE MARROW TRANSPLANTATION, 2009, 43 (04) : 301 - 305
  • [7] Effect of CD34+Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
    Pedraza, Alexandra
    Queralt Salas, Maria
    Gerardo Rodriguez-Lobato, Luis
    Charry, Paola
    Suarez-Lledo, Maria
    Martinez-Cibrian, Nuria
    Domenech, Ariadna
    Teresa Solano, Maria
    Arcarons, Jordi
    de Llobet, Noemi
    Rosinol, Laura
    Gutierrez-Garcia, Gonzalo
    Fernandez Aviles, Francesc
    Urbano-Ispizua, Alvaro
    Rovira, Montserrat
    Martinez, Carmen
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (03): : 181.e1 - 181.e10
  • [8] CD34+-selected stem cell "Boost" for poor graft function after allogeneic hematopoietic stem cell transplantation
    Mohty, R.
    Brissot, E.
    Battipaglia, G.
    Ruggeri, A.
    Sestili, S.
    Mediavilla, C.
    Belhocine, R.
    Dulery, R.
    Mohty, M.
    Malard, F.
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2019, 67 (03) : 112 - 114
  • [9] Effect of CD34+Total/Myeloid CD34+Cell Progenitors and B-Lymphoid Progenitors Within the Bone Marrow Grafts on the Hematopoietic Recovery After Hematopoietic Stem Cell Transplantation br
    Dalva, Klara
    Haskologlu, Sule
    Dalva-Aydemir, Sevim
    Oz, Memnune D.
    Ozturk, Aydin
    Ipek, Senay
    Demir, Haci A.
    Ertem, Mehmet
    Ilhan, Osman
    Gurman, Gunhan
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2022, 20 (10) : 937 - 944
  • [10] Peripheral Blood Stem Cell Harvest HPC Count Is an Effective Surrogate Marker for CD34+Cell Count in Allogeneic Stem Cell Transplant Setting
    Jamal, Aisha
    Khan, Mohammad Tahir
    Parveen, Sadia
    Rizvi, Qurratulain
    Farzana, Tasneem
    Zaidi, Uzma
    Borhany, Munira
    Siddiqui, Saima
    Ansari, Saqib Hussain
    Shamsi, Tahir Sultan
    TRANSLATIONAL ONCOLOGY, 2020, 13 (07):